Methods for treating amyotrophic lateral sclerosis
AssigneeThe Regents of the University of Michigan
InventorsEva L. Feldman, Ben Murdock, Stephen Goutman, Stacey Jacoby
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for treating, delaying progression of, or reducing the severity of amyotrophic lateral sclerosis (ALS) in a subject through administration of therapeutically effective amounts of agents (e.g., JAK kinase inhibitors (e.g., tofacitinib)) capable of interfering with central nervous system related natural killer cell (NK) levels and function.
Claims17
A method of treating, delaying progression of, or reducing the severity of amyotrophic lateral sclerosis (ALS) in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of an agent, wherein the therapeutically effective amount is sufficient to interfere with central nervous system related natural killer cell (NK) levels and function.
A kit comprising an agent capable of interfering with central nervous system related natural killer cell (NK) levels and function and instructions for administering the agent to a subject having or at risk of having ALS,
- wherein the agent is selected from AT9283, AZD1480, baricitinib, BMS-911543, fedratinib, filgotinib (GLPG0634), gandotinib (LY2784544), INCB039110, lestaurtinib, momelotinib (CYT0387), NS-018, pacritinib (SB1518), peficitinib (ASP015K), tofacitinib (formerly tasocitinib), and XL019.
A method of attenuating motor neuron vulnerability to NK cell activity, comprising administering to the patient a therapeutically effective amount of an agent capable of interfering with central nervous system related natural killer cell (NK) levels and function.
Dependencies are inferred from the claim text.